Menu

Wolfson Institute of Preventive Medicine

Search - ZOO
Search - K2
Search - Categories
Search - Contacts
Search - Content
Search - Newsfeeds
Search - Weblinks

Publications

We maintain an archive of past and current publications which can be searched by clicking on the links to the left or by using the drop down menus at the top of this page to search by author name, journal name or year of publication.

Alternatively you can use the search bar to look up a key word.

Our most recent publications are listed below.

Mangesh Thorat Publications

Authors

Publication Summary

Journal

Years

Agha RA, Fowler AJ, Saeta A, Barai I, Rajmohan S, Orgill DP, Afifi R, Al-Ahmadi R, Albrecht J, Alsawadi A, Aronson J, Ather MH, Bashashati M, Basu S, Bradley P, Chalkoo M, Challacombe B, Cross T, Derbyshire L, Farooq N Erratum to “Erratum to “The SCARE guidelines: Consensus-based surgical case report guidelines” [Int. J. Surg. 34 (2016) 180–186]” [Int. J. Surg. 36 (2016) 396], (S1743919116310305), (10.1016/j.ijsu.2016.11.021)). vol.47, () 151.
10.1016/j.ijsu.2017.08.568
International Journal of Surgery2017
Agha RA, Borrelli MR, Vella-Baldacchino M, Thavayogan R, Orgill DP, Pagano D, Pai PS, Basu S, McCaul J, Millham F, Vasudevan B, Leles CR, Rosin RD, Klappenbach R, Machado-Aranda DA, Perakath B, Beamish AJ, Thorat MA, Ather MH, Farooq N The STROCSS statement: Strengthening the Reporting of Cohort Studies in Surgery. vol.46, () 198 - 202.
10.1016/j.ijsu.2017.08.586
International Journal of Surgery2017
Thorat MA, Cuzick J Preventing invasive breast cancer using endocrine therapy.. vol., () .
10.1016/j.breast.2017.06.027
Breast2017
Oke A, Knox J, Tan J, Aigret B, Schmid P, Coleman RE, Cuzick J, Thorat MA Barriers to recruitment from primary care into a trial in secondary care settings: experience from the feasibility study of IBIS-3 trial. vol.18, () .TRIALS2017
Ussi AE, Rebolj M, Thorat MA, Bietrix F, Fauvel A-C, Hajdúch M, Hill C, Walker I, van Engeland M, Cuzick J, Meijer G Assessing opportunities for coordinated R&D in early cancer detection and management in Europe.. vol.140, (7) 1700 - 1701.
10.1002/ijc.30564
Int J Cancer2017
Thorat MA, Wagner S, Jones LJ, Levey PM, Bulka K, Hoff R, Sangale Z, II FDD, Bundred NJ, Fentiman IS, Forbes JF, Lanchbury JS, Cuzick J Prognostic and predictive relevance of cell cycle progression (CCP) score in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial. vol.77, () .
10.1158/1538-7445.SABCS16-P1-09-06
CANCER RESEARCH2017
Agha RA, Fowler AJ, Saeta A, Barai I, Rajmohan S, Orgill DP, Afifi R, Al-Ahmadi R, Albrecht J, Alsawadi A, Aronson J, Ather MH, Bashashati M, Basu S, Bradley P, Chalkoo M, Challacombe B, Cross T, Derbyshire L, Farooq N “The SCARE guidelines: Consensus-based surgical case report guidelines” [Int. J. Surg. 34 (2016) 180–186]((2016) 34 (180–186)(S174391911630303X)(10.1016/j.ijsu.2016.08.014)). vol.36, () 396 - 396.
10.1016/j.ijsu.2016.11.021
International Journal of Surgery2016
Agha RA, Fowler AJ, Rajmohan S, Barai I, Orgill DP, PROCESS Group Preferred reporting of case series in surgery; the PROCESS guidelines.. vol.36, (Pt A) 319 - 323.
10.1016/j.ijsu.2016.10.025
Int J Surg2016
Agha RA, Fowler AJ, Saeta A, Barai I, Rajmohan S, Orgill DP, SCARE Group The SCARE Statement: Consensus-based surgical case report guidelines.. vol.34, () 180 - 186.
10.1016/j.ijsu.2016.08.014
Int J Surg2016
THORAT MA Individualised benefit–harm balance of aspirin as primary prevention measure – a good proof-of-concept, but could have been better…. vol., () .
10.1186/s12916-016-0648-9
BMC Medicine2016
Guerrieri-Gonzaga A, Sestak I, Lazzeroni M, Serrano D, Rotmensz N, Cazzaniga M, Varricchio C, Thorat MA, Pruneri G, Leonardi MC, Galimberti V, Bonanni B, DeCensi A Benefit of low-dose tamoxifen in a large, single-institution cohort of high-risk ER-positive DCIS. vol.76, () .
10.1158/1538-7445.AM2016-1788
CANCER RESEARCH2016
Thorat MA A major flaw in "awareness of breast cancer and barriers to breast screening uptake in Bangladesh: A population based survey". vol.88, () 45 - 45.
10.1016/j.maturitas.2016.03.013
Maturitas2016
Thorat MA, Wagner S, Jones LJ, Levey PM, Bulka K, Hoff R, Sangale Z, II FDD, Bundred NJ, Fentiman IS, Forbes JF, Lanchbury JS, Cuzick J Prognostic and predictive relevance of HER2 status in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial. vol.76, () .CANCER RESEARCH2016
Thorat MA, Jones LJ, Levey PM, Elia G, Evagora CA, Bundred NJ, Fentiman IS, Forbes JF, Cuzick J Prognostic role and impact of multi-clonal ER and PgR expression in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial. vol.76, () .CANCER RESEARCH2016
Thorat MA Sentinel lymph node assessment in breast cancer patients receiving neo-adjuvant chemotherapy: to biopsy before or after?. vol.138, (2) 267 - 270.
10.1002/ijc.29692
Int J Cancer2016
Cuzick J, Cuschieri K, Denton K, Hopkins M, Thorat MA, Wright C, Cubie H, Moore C, Kleeman M, Austin J, Ashdown-Barr L, Hunt K, Cadman L Performance of the Xpert HPV assay in women attending for cervical screening. vol.1, () 32 - 37.
10.1016/j.pvr.2015.05.002
Papillomavirus Research2015
Cuzick J, Sestak I, Thorat MA Impact of preventive therapy on the risk of breast cancer among women with benign breast disease.. vol.24 Suppl 2, () S51 - S55.
10.1016/j.breast.2015.07.013
Breast2015
Cuzick J, Thorat M Preventing invasive breast cancer in women at high risk based on benign/in situ pathology. vol.24, () S11 - S11.BREAST2015
DeCensi A, Thorat MA, Bonanni B, Smith SG, Cuzick J Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake.. vol.9, () 595.
10.3332/ecancer.2015.595
Ecancermedicalscience2015
Pathmarajah P, Shah K, Taghipour K, Ramachandra S, Thorat MA, Chaudhry Z, Patkar V, Peters F, Connor T, Spurrell E, Tobias JS, Vaidya JS Letrozole-induced necrotising leukocytoclastic small vessel vasculitis: First report of a case in the UK.. vol.16, () 77 - 80.
10.1016/j.ijscr.2015.09.024
Int J Surg Case Rep2015
Cuzick J, Thorat MA PSA testing for prostate cancer screening--authors' reply.. vol.16, (1) e3.
10.1016/S1470-2045(14)71189-1
Lancet Oncol2015
Thorat MA, Cuzick J Reply to the Letter to the Editor "The harms of low-dose aspirin prophylaxis are overstated" by P. Elwood and G. Morgan. vol., () .
10.1093/annonc/mdu546
Annals of Oncology2014
Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, Ilic D, Key TJ, La Vecchia C, Lilja H, Marberger M, Meyskens FL, Minasian LM, Parker C, Parnes HL, Perner S Prevention and early detection of prostate cancer.. vol.15, (11) e484 - e492.
10.1016/S1470-2045(14)70211-6
Lancet Oncol2014
Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, Ford LG, Jacobs EJ, Jankowski JA, La Vecchia C, Law M, Meyskens F, Rothwell PM, Senn HJ, Umar A Estimates of benefits and harms of prophylactic use of aspirin in the general population. vol., () .
10.1093/annonc/mdu225
Annals of Oncology2014
Vasiljevic N, Ahmad A, Thorat M, Fisher G, Berney D, Moller H, Foster C, Cuzick J, Lorincz A DNA methylation gene-based models indicating independent poor outcome in prostate cancer. vol.14, (1) 655.
10.1186/1471-2407-14-655
BMC Cancer2014
Cuzick J, Thorat MA Preface. vol.202, () .
10.1007/s10555-010-9228-1
2014
Thorat M, Cuzick J Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population. vol.30, (1) 5 - 18.
10.1007/s10654-014-9971-7
European Journal of Epidemiology2014
Thorat MA, Cuzick J Role of aspirin in cancer prevention.. vol.15, (6) 533 - 540.
10.1007/s11912-013-0351-3
Curr Oncol Rep2013
Gökmen-Polar Y, Thorat MA, Sojitra P, Saxena R, Badve S FOXP3 expression and nodal metastasis of breast cancer. vol.36, (5) 405 - 409.
10.1007/s13402-013-0147-3
Cellular Oncology2013
Vasiljevi¿ N, Ahmad AS, Beesley C, Thorat MA, Fisher G, Berney DM, Møller H, Yu Y, Lu Y-J, Cuzick J, Foster CS, Lorincz AT Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer.. vol.16, (1) 35 - 40.
10.1038/pcan.2012.47
Prostate Cancer Prostatic Dis2013
Sainsbury R, Loddo M, Proctor I, Stoeber K, Williams G, Thorat M, Cuzick J Cell cycle algorithm correlates with grade of DCIS and p53 status, allows elimination of 'intermediate grade' disease and gives clinically meanignful information.. vol.72, () .
10.1158/0008-5472.SABCS12-PD04-08
CANCER RESEARCH2012
Duchnowska R, Jassem J, Goswami CP, Gokmen-Polar Y, Li L, Thorat MA, Flores N, Hua E, Woditschka S, Palmieri D, Steinberg SM, Biernat W, Sosinska-Mielcarek K, Szostakiewicz B, Czartoryska-Arlukowicz B, Radecka B, Tomasevic Z, Sledge GW, Steeg PS, Badve SS 13-gene signature to predict rapid development of brain metastases in patients with HER2-positive advanced breast cancer. vol.30, (15) .JOURNAL OF CLINICAL ONCOLOGY2012
Schneider BP, Radovich M, Hancock B, Kassem N, Sledge G, Nielsen KV, Thorat M, Mehta R, Badve S VEGFA Amplification/Deletion in Human Breast Tumors. vol.25, () 65A - 65A.MODERN PATHOLOGY2012
Cheol Kim D, Thorat MA, Lee MR, Cho SH, Vasiljevi¿ N, Scibior-Bentkowska D, Wu K, Ahmad AS, Duffy S, Cuzick JM, Lorincz AT Quantitative DNA methylation and recurrence of breast cancer: a study of 30 candidate genes.. vol.11, (2-3) 75 - 88.
10.3233/CBM-2012-0266
Cancer Biomark2012
Thorat MA Tackling breast cancer in India. vol.379, (9834) 2340 - 2341.
10.1016/S0140-6736(12)61017-4
The Lancet2012
Duchnowska R, Jassem J, Szutowicz E, Biernat W, Jankowski T, Och W, Staszkiewicz R, Chudzik M, Rogowski W, Flores N, Woditschka S, Li L, Goswami C, Thorat MA, Gokmen-Polar Y, Sledge GW, Steeg PS, Palmieri D, Badve SS RAD51 and brain metastases (BM) in patients (pts) with HER2+ breast cancer.. vol.29, (15_suppl) 634.J Clin Oncol2011
Duchnowska R, Jassem J, Szutowicz E, Biernat W, Jankowski T, Och W, Staszkiewicz R, Chudzik M, Rogowski W, Flores N, Woditschka S, Li L, Goswami C, Thorat MA, Gokmen-Polar Y, Sledge GW, Steeg PS, Palmieri D, Badve SS RAD51 and brain metastases (BM) in patients (pts) with HER2+breast cancer. vol.29, (15) .JOURNAL OF CLINICAL ONCOLOGY2011
Sojitra PM, Thorat M, Jain RK, Mehta R, Badve S Regulatory T-Cells in Breast Cancer Sentinel Nodes: FOXP3 Expression Analysis. vol.24, () 64A - 64A.MODERN PATHOLOGY2011
Vasiljevi¿ N, Wu K, Brentnall AR, Kim DC, Thorat MA, Kudahetti SC, Mao X, Xue L, Yu Y, Shaw GL, Beltran L, Lu Y-J, Berney DM, Cuzick J, Lorincz AT Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing.. vol.30, (4) 151 - 161.
10.3233/DMA-2011-0790
Dis Markers2011
Ademuyiwa FO, Miller A, O'Connor T, Edge SB, Thorat MA, Sledge GW, Levine E, Badve S The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. vol.126, (3) 797 - 802.
10.1007/s10549-010-1329-6
Breast Cancer Research and Treatment2011
McCune K, Mehta R, Thorat MA, Badve S, Nakshatri H Loss of ER alpha and FOXA1 expression in a progression model of luminal type breast cancer: Insights from PyMT transgenic mouse model. vol.24, (5) 1233 - 1239.
10.3892/or_00000977
ONCOLOGY REPORTS2010
Appaiah H, Bhat-Nakshatri P, Mehta R, Thorat M, Badve S, Nakshatri H ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer.. vol.10, (6) 600 - 614.
10.4161/cbt.10.6.12586
Cancer Biol Ther2010
Badve SS, Li L, Thorat MA, Gagnon RC, Ellis CE, O'Shaughnessy J, Blackwell KL, Baselga J, Sledge GW Differential gene expression analysis and correlation with outcome in HER2-positive metastatic breast cancer treated with HER2-targeted therapy. vol.28, (15) .JOURNAL OF CLINICAL ONCOLOGY2010
Ademuylwa FO, Miller A, Edge SB, Thorat MA, Sledge GW, Badve SS The effects of Oncotype DX recurrence scores on chemotherapy receipt in a multi-institutional breast cancer cohort.. vol.28, (15) .JOURNAL OF CLINICAL ONCOLOGY2010
Schneider BP, Radovich M, Hancock BA, Kassem N, Vance GH, Sledge GW, Nielsen KV, Mueller S, Thorat MA, Badve SS VEGFA amplification/deletion in human breast tumors. vol.28, (15) .JOURNAL OF CLINICAL ONCOLOGY2010
Badve S, Collins NR, Bhat-Nakshatri P, Turbin D, Leung S, Thorat M, Dunn SE, Geistlinger TR, Carroll JS, Brown M, Bose S, Teitell MA, Nakshatri H Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications.. vol.176, (5) 2139 - 2149.
10.2353/ajpath.2010.090477
Am J Pathol2010
Jain RK, Thorat MA, Mehta R, Polar Y, Morimiya A, Sweeney C, Beck S, Ulbright TM, Badve S Gene Expression Profiles of Classical and Spermatocytic Seminoma. vol.23, () 198A - 198A.MODERN PATHOLOGY2010
Thorat MA, Thorat PM, Vaidya HJ, Vaidya JS Analysis of temporal trends in the BMJ archive. vol.341, () c3306.
10.1136/bmj.c3306
BMJ2010
Gokmen-Polar Y, Mehta R, Tuzmen S, Mousses S, Thorat MA, Sanders KL, Turbin D, Leung S, Huntsman DG, Sledge GW Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes. vol.124, (2) 327 - 335.Breast Cancer Res Treat.2010
ADEMUYIWA F, THORAT M, JAIN R, NAKSHATRI H, BADVE S Expression of Forkhead- box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. vol.23, (2) 270 - 275.
10.1038/modpathol.2009.172
Mod Pathol.2010
McCune K, Mehta R, Thorat MA, Badve S, Nakshatri H Loss of ER alpha and FOXA1 expression in a progression model of luminal type breast cancer: Insights from PyMT transgenic mouse model. vol.24, (5) 1233 - 1239.
10.3892/or-00000977
Oncol Rep.2010
MCCUNE K, BHAT-NAKSHATRI P, THORAT M, NEPHEW K, BADVE S, NAKSHATRI H Prognosis of Hormone-Dependent Breast Cancers: Implications of the Presence of Dysfunctional Transcriptional Networks Activated by Insulin via the Immune Transcription Factor T-bet. vol.70, (2) 685 - 696.
10.1158/0008-5472.CAN-09-1530
Cancer Res.2010
Resetkova E, Reis-Filho JS, Jain RK, Mehta R, Thorat MA, Nakshatri H, Badve S Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. vol.123, (1) 97 - 108.
10.1007/s10549-009-0619-3
Breast Cancer Research and Treatment2010
Vaidya JS, Baldassarre G, Thorat MA, Massarut S Role of Glucocorticoids in Breast Cancer. vol.16, (32) 3593 - 3600.
10.2174/138161210793797906
Current Pharmaceutical Design2010
Badve S, Shen C, Thorat M, Li L, Gagnon R, Koehler M, Ellis C, O'Shaughnessy J, Baselga J, Sledge G Identification of gene expression profiles that predict response to HER2-targeted therapy. vol.7, (3) 5 - 5.EJC SUPPLEMENTS2009
Ademuyiwa FO, Thorat M, Nakshatri H, Badve S Correlation of FOXA1 expression with Oncotype Dx recurrence scores.. vol.27, (15_suppl) 11058.J Clin Oncol2009
Al-Azzawi H, Swartz-Basile D, Wang S, Dalbec K, Thorat M, Pitt H, Zyromski N Obesity promotes differential gene expression in pancreatic cancer. vol.69, () .CANCER RESEARCH2009
McCune K, Thorat M, Badve S, Nakshatri H A transgenic model for dietary intervention/chemoprevention strategies for metastatic breast cancer. vol.16, () 45 - 45.ANN SURG ONCOL2009
McCune KR, Bhat-Nakshatri P, Thorat M, Badve S, Nakshatri H Control of luminal type A intrinsic subtype enriched transcription factor network by insulin: implications of diabetes on breast cancer classification. vol.69, (2) 213S - 214S.CANCER RESEARCH2009
Duchnowska R, Jassem J, Shen C, Thorat M, Li L, Morimiya A, Zhao Q, Biernat W, Mandat T, Staszkiewicz R, Och W, Szostak W, Gugala K, Trojanowski T, Czartoryska-Arlukowicz B, Szczylik C, Nakshatri H, Steeg P, Sledge G, Badve S Molecular characteristics of matched brain metastasis (BM) versus the primary breast cancer (PBC).. vol.69, (2) 164S - 164S.CANCER RESEARCH2009
THORAT M, MEHROTRA S, MORIMIYA A, al. E COX-2 Expression Does Not Correlate with Microvessel Density in Breast Cancer. vol.76, (1) 39 - 44.
10.1159/000178154
Pathobiology journal of immunopathology molecular and cellular biology2009
THORAT M Comment on "Dynamic response to heat--a novel physical characteristic of breast cancer".. vol.7, (2) 173.
10.1016/j.ijsu.2008.12.002
International journal of surgery2009
HAMMOUD Z, BADVE S, ZHAO Q, LI L, SAXENA R, THORAT M, MORIMIYA A, RIEGER K, KESLER K Differential gene expression profiling of esophageal adenocarcinoma. vol.137, (4) 829 - 834.
10.1016/j.jtcvs.2008.08.052
J Thorac Cardiovasc Surg2009
THORAT M, ADEMUYIWA F, NAKSHATRI H, al. E Expression of FOXA1, Estrogen Receptor Associated Transcription Factor, Correlates with Oncotype Dx Recurrence Score. vol.89, () 72A - 72A.2009
AL-AZZAWI H, PITT H, SWARTZ-BASILE D, WANG S, DALBEC K, THORAT M, ZYROMSKI N Obesity downregulates innate and adaptive immunity genes in the pancreatic cancer microenvironment. vol.209, () S118 - S119.2009
Thorat MA, Rangole A, Nadkarni MS, Parmar V, Badwe RA Revision surgery for breast cancer: Single-institution experience. vol.113, (8 SUPPL.) 2347 - 2352.
10.1002/cncr.23839
Cancer2008
Badve S, Thorat M, Reis-Filho J Cytoplasmic expression of ALDH1 correlates with breast cancer subtypes. vol.53, () 26 - 26.HISTOPATHOLOGY2008
Resetkova E, Thorat M, Badve S Expression of ALDH1 (putative cancer stem cell marker) does not correlate with response to neoadjuvant chemotherapy (NACT) in breast carcinoma. vol.53, () 59 - 60.HISTOPATHOLOGY2008
Thorat MA, Badve S Estrogen- and progesterone-receptor status in breast cancer: Immunohistochemistry and quantitative reverse transcription-polymerase chain reaction assays show equivalency. vol.7, (9) .American Journal of Hematology/ Oncology2008
Duchnowska R, Jassem J, Thorat MA, Morimiya A, Sledge GW, Li L, Biernat W, Szczylik C, Steeg PS, Badve SS Gene expression analysis for prediction of early brain metastasis (BM) in HER2-positive (HER2+) breast cancer patients (pts). vol.26, (15) .JOURNAL OF CLINICAL ONCOLOGY2008
Duchnowska R, Jassem J, Thorat MA, Morimiya A, Sledge GW, Li L, Biernat W, Szczylik C, Steeg PS, Badve SS Gene expression analysis for prediction of early brain metastasis (BM) in HER2-positive (HER2+) breast cancer patients (pts).. vol.26, (15_suppl) 1019.J Clin Oncol2008
Thorat MA, Saxena R, Badve SS Regulatory T cells (T-Regs) in breast cancer sentinel nodes (SN): FOXP3 expression analysis. vol.26, (15) .JOURNAL OF CLINICAL ONCOLOGY2008
Thorat MA, Saxena R, Badve SS Regulatory T cells (T-Regs) in breast cancer sentinel nodes (SN): FOXP3 expression analysis.. vol.26, (15_suppl) 22175.J Clin Oncol2008
THORAT M, TURBIN D, MORIMIYA A, al. E Amplified in breast cancer 1 expression in breast cancer. vol.53, (6) 634 - 641.
10.1111/j.1365-2559.2008.03155.x
Histopathology2008
HAN-COCK B, RADOVICH M, BADVE S, THORAT M, AZZOUZ F, SCHNEIDER B Association of single nucleotide polymorphisms in angiogenesis genes with expression of VEGF and VEGFR-2 in breast carcinoma. vol.49, () 66.2008
Marchio C, Thorat M, Morimiya A, Savage K, Nakshatri H, Reis-Filho J, Badve S FOXA1: A prognostic and luminal subtype a marker in breast cancer. vol.21, () 45A - 45A.MODERN PATHOLOGY2008
THORAT M Five genetic variants associated with prostate cancer. vol.358, (25) 2740 - 2740.N Engl J Med.2008
THORAT M, MARCHIO C, MORIMIYA A, al. E Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. vol.61, (3) 327 - 332.
10.1136/jcp.2007.052431
Journal of Clinical Pathology2008
THORAT M, THORNTON H MRI breast screening.. vol.371, (9622) 1415.
10.1016/S0140-6736(08)60620-0
The Lancet2008
THORAT M, MORIMIYA A, MEHROTRA S, al. E Prostanoid receptor EP1 expression in breast cancer. vol.21, (1) 15 - 21.
10.1038/modpathol.3800970
Modern Pathology2008
THORAT M What caused the decline in US breast cancer incidence?. vol.5, (6) 314 - 315.
10.1038/ncponc1113
Nat Clin Pract Oncol.2008
Thorat M, Morimiya A, Sledge G, Badve S Characterization of estrogen receptor positive breast cancers: gene expression analysis of archived tumours. vol.106, () S243 - S243.BREAST CANCER RESEARCH AND TREATMENT2007
Thorat MA, Badve S Prognostic factors in invasive breast carcinoma: Do new molecular techniques/profiling add significantly to traditional histological factors?. vol.13, (2) 116 - 125.
10.1016/j.cdip.2006.12.002
Current Diagnostic Pathology2007
Basu S, Nair N, Thorat M, Shet T Uptake characteristics of FDG in multiple juvenile cellular fibroadenomata of the breast: FDG-PET and histopathologic correlation.. vol.32, (3) 203 - 204.
10.1097/01.rlu.0000255037.59458.ff
Clin Nucl Med2007
BADVE S, TURBIN D, THORAT M, Morimaya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H FOXA1 expression in breast cancer - Correlation with luminal subtype A and survival. vol.13, (15) 4415 - 4421.
10.1158/1078-0432.CCR-07-0122
Clinical Cancer Research2007
THORAT M Gene-signature-based prognostic tools in breast cancer: not yet. vol.369, (9571) 1428 - 1428.
10.1016/S0140-6736(07)60663-1
2007
THORAT M, PARMAR V, NADKARNI M, al. E Radiation therapy for ductal carcinoma in situ: Is it really worth it?. vol.25, (4) 461 - 462.
10.1200/JCO.2006.09.1645
2007
THORAT M Should we undertake an MRI breast screening trial?. vol.370, (9603) 1902 - 1902.
10.1016/S0140-6736(07)61803-0
2007
Thorat M Tuning into the genetic orchestra using microarrays: limitations of DNA microarrays in clinical practice - Response. vol.3, (12) .
10.1038/ncponc0698
NAT CLIN PRACT ONCOL2006
Thorat M Tuning into the genetic orchestra using microarrays: limitations of DNA microarrays in clinical practice.. vol.3, (12) E1.
10.1038/ncponc0699
Nat Clin Pract Oncol2006
Thorat M Trastuzumab for early breast cancer.. vol.367, (9505) 108.
10.1016/S0140-6736(06)67953-1
Lancet2006
Thorat MA Are there distinct lymphatic flow patterns in the breast?. vol.66, (5) 1040 - 1041.
10.1016/j.mehy.2005.12.018
Med. Hypotheses2006
THORAT M, DATAR R, JOSHI N Cancer immunotherapeutics: Raising the ante. vol.19, (3) 140 - 150.2006
BADWE R, D'CRUZ A, MISTRY R, al. E Developing countries: An evolving opportunity for oncologic research. vol.30, (7) 1173 - 1176.
10.1007/s00268-006-0080-y
2006
THORAT M Medical research in India. vol.368, (9536) 643 - 644.
10.1016/S0140-6736(06)69239-8
2006
Kida Y, Thorat MA, Badwe RA Autoantibodies in prostate cancer [2]. vol.353, (26) 2815 - 2816.
10.1056/NEJMc055428
New England Journal of Medicine2005
Thorat MA, Badwe RA Autoantibodies in prostate cancer.. vol.353, (26) 2815 - 2817.
10.1056/NEJMc055428
N Engl J Med2005
THORAT M, BADWE R Autoantibodies in prostate cancer. vol.353, (26) 2816 - 2816.2005
BADWE R, THORAT M Does primary tumor location have prognostic significance in operable breast cancer?. vol.2, (8) 396 - 397.
10.1038/ncponc0249
2005
THORAT MA Herceptin in early breast cancer: a call for judicious use.. vol.18, (6) 315 - 317.2005
THORAT M, THORAT P Privately versus publicly managed primary healthcare. vol.18, (5) 274 - 275.2005
Thorat M Optimum cancer care--an unaffordable goal?. vol.5, (9) 530.
10.1016/S1470-2045(04)01575-X
Lancet Oncol2004
Badwe RA, Thorat MA, Parmar VV, De Salvo GL, Del Bianco P, Zavagno G, Munster AM, McMasters KM, Veronesi U, Maisonneuve P, Krag D, Ashikaga T Sentinel-Node Biopsy in Breast Cancer [1] (multiple letters). vol.349, (20) 1968 - 1971.
10.1056/NEJM200311133492017
New England Journal of Medicine2003
BADWE R, THORAT M, PARMAR V Sentinel-node biopsy in breast cancer. vol.349, (20) 1968 - 1968.2003
Badwe RA, Thorat MA, Havaldar RW, Komorowski AL, Wysocki W, Somlo G, Levitt SH, Fisher B, Anderson S, Bryant J Radical and simple mastectomy [3] multiple letters. vol.347, (26) 2170 - 2171.
10.1056/NEJM200212263472615
New England Journal of Medicine2002
BADWE R, THORAT M, HAVALDAR R Radical and simple mastectomy. vol.347, (26) 2170 - 2170.
10.1056/NEJM200212263472615
2002
Cuzick J, Thorat MA Preventing invasive breast cancer using endocrine therapy. vol.Volume 32, Supplemen, () S7 - S8.
10.1016/S0960-9776(17)30071-1
The Breast
Return to top